According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...

The rest of Europe could learn from them. Politicians in Brussels are perpetually searching for ways to invigorate the ...

Explore 13 of the most technologically advanced countries leading in innovation, research, and technological development ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

The proposed Biosecure Act as well as the diversification of American and European firms away from China are expected to help ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking ...

Developers of medicines known as “incretins” have been putting their therapies to such a test. Already, Novo showed its ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...